“Adoption of Tumor Treating Fields (TTFields)”
Tumor Treating Fields (TTFields) therapy, which employs low-intensity electrical fields to interfere with cancer cell division, is gaining significant attention in the treatment of Glioblastoma Multiforme (GBM). The FDA-approved Optune device, which delivers TTFields, has demonstrated promising results in clinical studies, particularly in improving progression-free survival and overall survival rates in patients with newly diagnosed GBM. As evidence of its efficacy continues to grow, the adoption of TTFields in clinical practice is increasing. This non-invasive treatment method offers a novel approach alongside traditional therapies such as surgery, radiation, and chemotherapy, presenting an alternative for patients who may not respond well to conventional treatments. The integration of TTFields into treatment regimens is becoming more common as healthcare providers aim to provide more comprehensive, multi-modal treatment options for GBM patients.
